Shares of Hims & Hers rose 7.59 percent on Wednesday to finish at $33.88 apiece as investors resorted to bargain-hunting ...

Polen Capital, an investment management company, released its “Polen Global Growth Strategy” fourth-quarter 2024 investor ...

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of ...

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

Launched in 2021 with a de-novo investment from Golden Gate Capital in partnership with Stonehill CEO Jay Parkinson, Stonehill is an environmental services business that enables energy customers to ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Danish drugmaker Novo Nordisk is prepared to enter the Indian market and other markets with its blockbuster drug Ozempic, despite losing patent exclusivity early next year. “Even as we face ...

Novo Nordisk (NVO) plans to run studies on how its GLP-1 class of weight loss/diabetes drug can help people deal with addiction, Martin Holst Lange, the Danish pharma’s head of development, told ...

Europe’s largest pharmaceutical firm, Novo Nordisk, has announced that it will offer its most popular weight-loss drug, Wegovy, for less than half of its listed price. This follows a similar ...

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured and underinsured individuals to be able to pay cash for its weight ...

Judge allows drugmaker into fight between compounders, FDA Maker of Wegovy has good cause to intervene, court rules Novo Nordisk A/S can intervene in a lawsuit between the FDA and drug compounders ...